Bruch’s membrane heparan sulfate retains lipoproteins in the early stages of age-related macular degeneration
Proceedings of the National Academy of Sciences · 2025
DOI: 10.1073/pnas.2500727122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Christopher B Toomey und 19 weiteren Autor:innen. Beteiligte Einrichtung: Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, CA 92093. Hauptthemen laut MEDLINE: Heparan Sulfate, Macular Degeneration, Bruch Membrane, Lipoproteins. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, International Retinal Research Foundation (IRRF), HHS | NIH | National Eye Institute (NEI).
Abstract (Originalsprache)
Lipoprotein retention in Bruch’s membrane is a key event in the pathobiology of early and intermediate age-related macular degeneration (AMD). However, the mechanism of lipoprotein retention in BrM is unknown. Given the established role of glycosaminoglycans (GAG) in binding lipoproteins, our laboratory sought to determine the role of GAGs in AMD BrM. In this study, BrM GAG content in AMD pathobiology was analyzed in human postmortem tissue. Strikingly, increased levels of highly sulfated heparan sulfate were present in AMD Bruch’s membrane as compared to non-AMD samples. In addition, using scanning electron microscopy of postmortem AMD tissue, we show aggregates of lipoprotein-like particles on the retinal pigmented epithelium side of Bruch’s membrane adjacent to heparan sulfate. We also show that heparin displaces lipoproteins rich in apolipoprotein A1 from human BrM, suggesting their identity as high-density lipoproteins. Using human BrM immobilized to quartz crystal microbalance biosensor (QCM) chips, we show that heparan sulfate is required for lipoprotein binding to BrM and soluble heparan sulfate can remove lipoproteins bound to BrM. Thus, our data establish that heparan sulfate regulates lipoprotein deposition in AMD BrM. These findings provide a foundation for targeted therapies capable of either preventing lipoprotein accumulation or removing drusen in the early and intermediate stages of AMD prior to vision loss.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, CA 92093.
- Glycobiology Research and Training Center, University of California San Diego, La Jolla, CA 92093.
- Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA 92093.
- Waitt Advanced Biophotonic Core, Salk Institute, La Jolla, CA 92093.
- Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins Medical Institute, Baltimore, MD 21287.
- Attana AB, Stockholm, Sollentuna 191 62, Sweden.
ORCID-Profile: Christopher B Toomey, Savanna Pflugmacher, Jessica Rodriguez, Madeline Mozafari, Sima P Omran, Jill Hauer, Chelsea Painter, James T Handa, Jeffrey D Esko
Förderung
- NEI NIH HHS
- International Retinal Research Foundation (IRRF)
- HHS | NIH | National Eye Institute (NEI)
- Research to Prevent Blindness (RPB)
- Foundation Fighting Blindness (FFB)
- HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)
- Novartis AG | Alcon | Alcon Research Institute (ARI)
- NIGMS NIH HHS
Zitieren
APA
Toomey, C. B., Pflugmacher, S., Park, K., Pihl, J., Weiser Novak, S., Rodriguez, J., Jalali, M., Jung, J., Mozafari, M., Omran, S. P., Pormir, C. K., Hauer, J., Painter, C., Walker, E., Huang, A. S., Boassa, D., Handa, J. T., Aastrup, T., Gordts, P. L. S. M., & Esko, J. D. (2025). Bruch’s membrane heparan sulfate retains lipoproteins in the early stages of age-related macular degeneration. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2500727122
Vancouver
Toomey CB, Pflugmacher S, Park K, Pihl J, Weiser Novak S, Rodriguez J, et al. Bruch’s membrane heparan sulfate retains lipoproteins in the early stages of age-related macular degeneration. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2500727122
BibTeX
@article{Toomey2025,
author = {Toomey, Christopher B and Pflugmacher, Savanna and Park, Kamalu and Pihl, Jessica and Weiser Novak, Sammy and Rodriguez, Jessica and Jalali, Maryam and Jung, Jaesoo and Mozafari, Madeline and Omran, Sima P and Pormir, Cameron K and Hauer, Jill and Painter, Chelsea and Walker, Evan and Huang, Alex S and Boassa, Daniela and Handa, James T and Aastrup, Teodor and Gordts, Philip L S M and Esko, Jeffrey D},
title = {Bruch’s membrane heparan sulfate retains lipoproteins in the early stages of age-related macular degeneration},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
doi = {10.1073/pnas.2500727122}
}
EUVIMED